ILMN earnings analysis
What we found in ILMN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Illumina, Inc. reported Q1 2026 revenue of $1.09 billion, marking a slight increase from the previous quarter's revenue of $1.04 billion and surpassing estimates. The company also reported GAAP diluted EPS of $1.15, exceeding analysts' expectations and reflecting a strong performance driven by continued demand for its genomic products.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Estimates
- Actual revenue was $1.09 billion, beating estimates of $1.07 billion by 1.4%.
- Strong EPS Result
- Reported EPS was $1.15, exceeding the expected $1.05 by 9.5%.
- Improved Free Cash Flow
- Free cash flow for the quarter improved to $219 million.
- Positive Segment Trends
- Segments related to genomic research and clinical oncology showed solid growth.
- Guidance Raised
- Full-year revenue guidance adjusted to $4.52B-$4.62B, an increase of $20 million.
- Continued Demand Growth
- Management highlighted strong ongoing demand, particularly in the genomic sequencing market.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cost Implications
- Increased costs related to R&D could impact margins.
- Regulatory Uncertainty
- Ongoing regulatory changes in the genomic and healthcare sectors pose risks.
- Integration Risks
- Challenges could arise from ongoing integration of new technologies.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.15
What they said about what is next.
Revenue guidance raised by $20 million at the midpoint and EPS guidance increased to $5.15-$5.30.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ILMN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever